Boehringer Ingelheim Chemicals Closing Virginia API Manufacturing Facility - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Boehringer Ingelheim Chemicals Closing Virginia API Manufacturing Facility



Boehringer Ingelheim Chemicals Inc. (BICI) will close its Petersburg, Virginia plant at the end of 2014. According to an Aug. 15, 2013 BICI press release, the facility will continue normal operations through the remainder of 2013 and phase out operations the following year. The closure will impact 240 employees through a multistage process starting in December 2013.

The Petersburg facility manufactures active ingredients for the pharmaceutical industry. BICI’s parent company, Boehringer Ingelheim, conducted a review of its current manufacturing capabilities worldwide, as well as needs in the industry, and determined that it had more capacity than the marketplace can sustain. BICI considered selling the facility but was unable to find a buyer. The company said it will begin working with its customers immediately to ensure a smooth transition to new suppliers.

Source: Boehringer Ingelheim Chemicals

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here